REGISTERED COMPANY NUMBER: 07955451 (England and Wale$} REGISTERED CHARITY NUMBER.. 1147457 R•port ofthè Trusts•$ and Flnon¢lal Ststgmgnts for th¢ Year Ended 31 Dgwnber 2022 for THE HPV ANO ANAL CANCER FOUNDATION UMITED Kmx Crop￿1 LLP charte￿ Aco)untants 65 Leadenhall Sireet London EC3A 2AD THE HPV AND ANAL CANCER FOUNDATION UMITED Contènts of the Finaneial Statements for the Year Ended 31 December 2022 Pa Rèl•rène• and AdmInIstratl￿ D•tslls Report of tho Truste•8 2 to 14 Indopandont Examln•r's Rèwt 15 Statement of Flnanclal Actlvlties 16 Balanc• She•t 17 Not•$ to lh• Flnan¢l¥l St¥t•m•nts 18 to 26 D•tall•d Stst•m•nt of Flnanclal ActSvbtS•• 27 to 28 THE HPV AND ANAL CANCER FOUNDATION UMITED R8fer8nce and Administrative Detai for the Year Ended 31 December 2022 TRUSTEES C Armada J Almada T ￿rnad8 C Leve REGISTERED OFFICE 128 Cty Road Lon(h)n EC1V 2NX REGISTERED COMPANY NUMBER 0795S451 IEnglaThJ and Wales) REGISTEREO CHARir NUMBER 1147457 INDEPENDENT EXAMINER Knox Cropper LLP Chartered Accountants 65 Le8denh811 Street Lon( EC3A Z4D SOLICITORS Stcffle KiThJ 16 St. John's London EC1M 48S BANKERS HSBC 455 Strand Lond WC2R ORH Page 1 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 The trustees who are also directors of Ihe chality for the purposes ol the Companies Act 20(￿, present their rewl with the financial statements ol the charity for the year ended 31 De￿mber 2022. The trustees have adopted the provisions of Accwnbng and ReFM)rbng by Chanbes.. Statement of Rewrnmended Practice applicab￿ to (*arities p￿paring their acc￿nts in acwrd8n¢e wth th8 Financial Reporting Standard ap￿1¢ab￿ in the UK and R8publi¢ of keland IFRS 1021 {effectivo 1 January 20191. The HPV and Anal Can￿r Foundation Limited is a United Kingdom IUKI subsidiary ol The HPV and Anal Can￿r Foundation in the Unrted States ol America IUSAI (Charity EIN.. 27-32175201. which was established April 2010. All work undetsken by th8 UK FourKl8tion 15 in ¢c4labora￿ its parent. The HPV and Anal Cancer F￿nd8tK￿ Limited is a dwrit8tye (x)mpany limrted by sh8rgs. ifKX)rpor8tgd in the UK on the 20th February 2012 and registered as a d)arity on the 25th May 2012. Thè company was established through its Artides ol Assco"al"on. which estat4ished the objects and powers ol the charitsble company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA. The HPV and An81 Cancer Foundaknn IM)8rd consisls of lour member5. The direciors are responsible for the lègal, financial, program and managemonl ovwswjhl ol the ¢harity. The board held its annual meetirTrg on December 26. The daily ￿SponSibl11t1eS and Missh￿ of the F(MJThJab"on a￿ exec(rted by the teams in the USA and the UK. In thè latt8r, the Dir8ctcw ol UK opwai￿$ is respO￿bla for th8 coordinal#)n of daY-l￿aY activities. When the Trustee3 advertise fu new board membets. caThYidates are sourced from the general public. A dNerse mix Of S￿.11$ and backgrounds are soughl. Prostwtsve trtjstees are Interviewed prior to aptK)illtmenl. As part ol thèir induction. new trust8ès arè given an ovèM•w ol Ihe worfK of Th& HPV and Anal Cancèr Foundation in add￿'On to copies of the organization's financial documents. b￿aW9. and policA8S. Rlsk Manaymènt The truste•s of the Foundatw hdd th8 responsibilty of safeguardin9 th& chanvs assets and are satisfiad that systems are in pla&8 to mitwJat6 those risks the charity may face. FINANCIAL RPIIEW It is irnportant to nots that the parent and subsrtdiary organcations operate as one entity in achieving the mission of the organisalion. The revenue lor Ihe chanty is de￿ndent on donats'ons from the public. Income for the UK HPV and Anal Cancer FoundaDon in 2022 was £154.892 and ex￿TrYi1Ure was £173.009. Reserves Pollcy The reserves policy is to rnainlain a minimwn thal enables Ihe UganiSati￿ to meet its financial commitments for the year, including 9ranl$, (x)ntr8Cts, staff saLqrig8. Page 2 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES Objective5 and aims Publlc Benefit The trustees have refefTed to the guidarK* ¢xntained in the Charity Commission's general guidance on public benefit when reviewin9 the charity's aims JKI (*)jeobves 8rKI in planning fuiure athrb85. History The Foundation was first established in the USA in 2010 by siblings wtho h)st their mother. aged 53, to stage IV HPV-relaled anal cancer. Fnjstrated by the limrted therapeutic and o)mmunity 5UPPOrt available to her, they created the organisation ¢0 f11 Ihe vo*Y ￿USed by sC8nt public, sry8nbfic and rnedical ftus on thi8 di5ea$& and its eause, the human papillomavirus IHPVI. HPV rauses anal cancor and at least rive other cancèrs, amounting to 5% 01 cancers work1￿7d&. Thèsè canc•rs are prèvèntab￿. In 2012, the or9anizalion expanded to the UK wilh 2013 as ils fI￿l full operabonal year. Mission Th8 HPV and Anal Cancèr Foundats"on 6mFx)wèrs anal cancer pats.ènts and a￿l￿rat&S prèvention and sèarch mèthods that aliminalè anal eancw8nd thè virus Ihat causes Ihè majority ofcasas, HPV. Obl•¢Uv - Highlight tha ralavance of human papllomavirus IHPVI in contracting cancer, Advocate for preventwjn Meth￿￿S that wll end anal cancer and HPV4eLaled cancers, induding gender-neutral vaccination.. - Accelerate a cure lor the 5°A of all cancers Ihat are caused by HPV, with 8 focus on anal cancer,. and - Provide support for survwors, caregivers, ￿lents$ts and provKlers (x)nne¢ted to an81 cancer. Th• Need A lundamentsl ot4ective of the Foundation's th is to reduce Ihe inlyden￿ of anal cancer and other HPV-rel818d cancers. HPV is 8 véry common skin virus that néaty èvery sexually activ8 P8rson wll 98t at some point In their lives. HPV affects both men aThJ women an¢J is ffjswnsiblè for 5Y¢ of tha wor*J's cancer burden. HPV causes cancers of the anus. cervix, h&id and neck, penis, vagina, and vulva. Protedion against HPV through universal HPV VaMna￿On is a critical publK health goal. With HPV identified as a cause of six different types of ￿ncer. and 5% of canc2r cases worldwide. il is imperabve Ihat we prolect th$ $ntire popul8tw againsl it. The most effective mWh(Kl to redu￿ can¢*rs related (o HPV is to pr9vent inits"81 infaction ol the virus through immunisatKJ). Thè F(MJnda*"on achievas this imwrtant airn through its efforts to advan￿ equal access to HPV protection for bolh boys and girfs through gender-neLrtral vaccination against the virus. Al Ihe inlrcmjuction of Ihe vaccine in most o)untries. only girls were able to receive this life-saving intervention while boys were generally exclud&J. The Foundabon uealed and led the co8litions in the US and UK to ensure all chiklren have equal a(uss to protection ag8inst these c3ncgrs. The US ach18V8d th8 rn1185tone of recotnm8nding HPV protection to al thikJr8n in 2011. Following the FoLJndation's five-year advocacy campaign in the UK, schcN)l-based HPV vacanat￿n for boys began in September 2019. Our focus is on securing Ihe same protection for trN)ys as well as girtg acfOSS Europe, and beyond. While we work io prevent luture cases. it 15 also fvndamenlal that SC￿ntifiC and medical disparities are address￿1 for the tx)pulation that will (x)ntinue to be dIagr￿￿d wilh HPV-related Gqncers like anal rancer. Treatment options have barely progressed since the 19705 and rninirnal research has been undertaken in new therap*s. The medKxI and suentsfic communbb.es need ￿tter research ti¥)Is and invèstment in novel ideas to deveknp a cure. Page 3 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 The stigma surrounding anal cancer remains c¥)e of the ￿ntral chaI￿ngeS to Improving outcomes for anal cancer patients. Unfortunatdy, many medical centres wovKle only limited information specffic to the experience ol anal cancer. Many patients feel isoLated and lack the sUp[￿rt and educational resources that signfficanty improve qualty of lrfe during and aftertrealment. Strategie5 to Athieve Our Goals We achieve our mission in the UK and US through Cdlaboratlc￿ wlh scientists, dinicians. suNivors, organisath)ns. and govemment agenues.. edwtion of Stake￿￿er$ and the general public.. survivor support., and investrnent in the medical and srienlific community to end HPV and the Cancers it causes. Specificalty, W8 take action lo desligrnab'ze arKI raise awareness aLK)u¢ HPV. HPV-related can¢xrs, and anal rancer.. inueas8 8CC85S to th8 HPV v8can8', irnprove sue8nin9 prot￿015 and prevent8ts'v8 c3re.' empower 8n81 ¢an¢sr Ihrtv$rs', and a￿lerate a ¢uro lor anal canw and oth¢r HPV4¢1ats(l illne$s¢$. Page 4 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES AND ACTIVITIES KEY ACHIEVEMENTS IN 2021 NOMAN Is an Island The NOMAN is an Island Campaign raises awareness atK)ut th8 HPV-related car￿er epidemic in men and women and educates about the imwrtance of universal HPV vawnation. while challervjing p8rti¢ipants to èxtrerne 8nduranc8 races a(xoss the workl. It is through 5uth extrem8 feats ol athletiasm that NOMEN honour the struggle and isoktion that many Ca￿er patients feel. NOMAN has been an incredibty sUC￿$ful campaign. Since Tts inaugural event in 2013 with the Barcelona Ibvza.. Row to End HPV. over 150 individuals- and their hundreds of supporters- have embraced the cause afbd wr values. These NOMEN have raised 8warenes8 8bout HPV-cancer8 on a lo¢al, natthal, and intem8lK)nal as well as funds to suwyt (xjr kwf8mmes. The passion of our participants ne￿r ceases to amaze us. espeaalty in the context of the COVID-19 pandemic. The NOMAN carnpa￿n implemented the necessary parameters and covid regujats'ons to enab our scheduk8d enduranc• and awareness events lo lake place. 2022 saw NOMAN riders lakè on Haulè R(yJt8 &V8nts al Dwuèz and Davos. Thè Hautè RoLrtè is th8 workl's most prestKJious cycling event amateur cydists. Thè faces provide unparal¢el*d èxperiencès wrth 3- or 74ay professional road cycling ￿ents in the most Icon￿ cyding destinat￿9 w0ddw￿fr. During the 34lay events. riders lake on som8 300km and ao(x)m+ of verbcal ascent. testsng thernselves against the most infamous climbs in Ihe worfd, all in Ihe name of rnising awareness of HPV-reLqted cancers. Additionally, at each event all partiCiP8nts were given our END HPV socks to Iwjht vp ¢he (Jimbs and generate conversation about our work to èliminate HPV canc8ts. NOMAN C￿fOUnd￿r Tristan Amada also spok* about our mission to eliminate HPV eancers at the pre41age bnefing event. Bad( in the United lQ'ngdom. NOMAN nders also to)k on Ride Lcffjdon Esse*s new route, racAng through the streets ol the camal and the suThounding r￿n1rys￿e. We thank all our alhletes for their sacnfice and energy as NOMEN. Wa look fornvard to 2023 and buldlng UFth) tyjr Haute R£￿te pathèrship and thè 10th annlvèrsary adi￿on ol our Barcelona . Ibvza.. Row to End HPV. HPV ACTION EUROPE NETWORK In 2018 and 2019, Ihe Foundation was invdved in discussions to esta￿lsh an advocacy campaun in Europe to introduce gender.neutral vaccination across the reg￿￿ and ￿mpletelY eliminate HPV-rdated diseases. NOMAN has partnered wilh the Euro￿an Can¢xr Organisation IECOI to achieve this mission. ECO works to r8duc8 the burden of cancer 8nd ifflprov8 out(x>mes arKI th8 qU81ity of Gqf8 for c8n(xr p8ti8nis through multidisciplinary inits'abves. As the European not-for-profit federats.on ol member organisations working in cancer. they convene oncokjgy professionals and patients lo ag￿ on FM)licy. advocate lor positive change, and be the united Vol￿ ol the European Can￿r o)mmunty. Together with ECO. the Foundation looks forward to working with European policy makers to end the sufieriTrJ caused by HPV cancer5. In 2021, we achi8V8d a mileston8 by for th8 first brne a txKnmilm8nt to elitninate HPV cancers in Europ8'S Beating C8n¢or Plan. The HPV A¢bon Nglwork buim on this m8ior su(tsss th thg foll¢)wing achievements in 2022. Published research mapping the current state of HPV vaccination and cervical screening programmes across the European region Page 5 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES Through this mapping exeruse. we have been ab￿ to identify nations that are activety addressing HPv-lndu￿d cancers and. more cxucjally. those that are laggirvJ behind. In various o)untries across the Europ8an R8gK)n, inth8tlV8S SLth as HPV vac£inalK)n and c£rviGql Ggncer screening progr8ms 8r8 riotab absent. Even among those wilh wdcanab(x) efft)rts. a gender-neutral apprtsach is not universally adopted. Notably, numer(yJs countries with established vacanal¥)n and $c￿enI￿a initiatives are encc¥Jntering challenges in achieving optimal Servi￿ utilisalion. The￿ remains a substanb'al amount of work to be done lo eliminate HPV Can￿rS as a public heath concem. Examining the state of HPV pr8v8ntion across the WHO Europ88n region (WHO EURO). this dat8 co118cb.on and analysis will infomi thè HPV Action Europe Network's strategy to implement change. Armed with the invaluab￿ insights prowd8d in this report, wè arè committèd Io 8xpeditsng 8cbons at thè r8gion81 lèvèl. Addititsnally, we aim to lend tyjr SUPFX)rt lo Ihe advctacy endeavours ol HPV organisations within individual countries. This cdlaborats've approach is aimed at ensuriThJ that all healthcare systems take the ne￿SSary steps to effectivety safeguard their popuL8tions. ¥thich o)uld to the prevention of nearty 100.000 cancer cases annualty. Published an 'umbrella review ol interventions used to improve HPV vaccine uptake in children, adole5￿nts and yotsng adults. T￿ r•sults w•re also publl*hod In thè Joumal STI. Tha HPV Action Ne￿ork conducted an imwrtant revièw ol published evidènce. identifying vark)us ¢x)Ildes and programmes that have improved intention an¢J uptake rates for HPV vaccination including printed materials. SMS based health information. lac&t￿a￿8 presentations and O&A sessions. HPV vaccination is easy to deliver, has immediate positive health impxts, and is highly efficac40us, making rt one of the most effective cancer prevention strategies available. The findings of ￿1$ review will be disseminated widely, wrth the aim ol ancouraging lh$ best possibb uso ol tIMs evid$nc& in HPV vacanalion pr¢grammès across Europg and beyond. HPV vaccination rates for girfs in Europe other parls of the worfd are hvJhly variable, ¥wth only European countries achieving a gJ/v uptske ol all vaccine doses for girfs. whi￿ some countries have m8n8ged to achieve over 70Wo uplake, others h8¥e r81es telow 50%, wth at ￿851 Tr)untn'es vaccinats'rrfJ fewer than 10&/0 019lrts. The main reason lor these suwlimal vacanabon rates is low vacane confidence among parents. carers, and young people theMse￿es. This may be due lo inadequate infom)ation, distrusl in health aulhorilies and vaccine rn8nuf8ctu￿rs. and concems regarding ¥8￿•ne safety. However. inlerventions can improve vaccine ¢onfiden¢& 8nd increase uptake rate$. Successfully applied for EU4Heallh fvnding for the year PROTECT*UROPE project which will tocus on increasing HPV vaccination uptake in EU member states. The EU4Heath programm was adopted as a reskY)nse to the Cov1￿19 pandemic and to relnforce crisls preparedness in the EU. The pandemic hwJhI￿hted (he fragility ol national health systems. The EU4Health programme ¥wll bring a contribution lo Ihe longlemi heatlh challenges by buikling stronger. more resilient and more accessible health systems, thrwgh financial support frorn the European Union. Through th15 funding, the PROTECT*UROPE project wll champK)n g8nd8r-neutral HPV v8ccin8tion in th EU to protect everyone against HPV cancers. by prowding inlomwtion and guidance to EU Member States on.. How healthcare professKJnals can better cunmunicate direclty wih young people and their parents or Ggregivers. - How public heath messaging on HPV bè tsik)red to bèttffi resonate wth young peoplè and thsir parènts or caregivers. How other inrh)vative approaches. such as bundlirrfJ various adobscent Va￿aneS, 0)U￿ improve HPV vacone uptake. This project wll ¢x)mrnence in January 2023. Page 6 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES Other achievements for the HPV Actmjn Nemrrt in 2022 ind￿le.. Commissioned 'HPV Changemakets. to higNKJht the ￿rSOnal stsxiès of individuals who havè successfijlly made the case lor change in the field ol HPV cancer eliminatic¥) in theif own countries. Started work on pilot prqects in Romania and BukJaria to devekp mU￿-0rgan1SatIOn adv￿￿￿ campaigns as part of the Action Now on HPV project. R85ponded to the WHO Europe consutt81K)n its Roadm8p for the Elimination of Cervical Can￿r 8nd made the ease for WKler action in a ￿esentati￿ to the WHO Euro[￿ Re9itsnal Committee meeting in Sèptèmbèr. Futurn plans In 2023 and bèyond, HPV Ath"on Nthrk wil: - Encourage and SUPFMXt the EC and EU Memter States to Im￿ement Europe's Bea￿.ng Can￿r Plan. - stsrt work on PROTECTEUROPE. - Make the case for action to address the impad ofthe pandern￿ on Vac¥)nati￿ and scxeening programm#3. - L8unch'HPV Ch8ng&m8kers.' L8unth tha pilot advocACy PfOj8ds in Romania Buwria. The n6xL stèp will b9 to idèntify oth8r thuntri$$ in the European region where a ￿mI￿r approach can b& devek4)8d. - Continue to support the HPV Coalition in the UK. ' Advocate for the inclu&on ofgenderryneutral HPV vaccjnation in Ihe European Code Against Cancer. HPV co81ib.on In October, the NOMAN Campatqn was proud to join forces Jo's Cerwcal Cancér Trust to launch and co.chair the new HPV cOal￿.0n in the United ￿ngdOrn. The HPV Coalrtion is an expert advisory group of ￿adIng patienl groups, professional groups, clinicians, and expert individuals who have ¢om& i(yJ&ther lo infomi and advance lh& UK'S joumey towards elimination ol HPV-r*lat6d c2ncèrs - cancèrs whid) acctyJnl for 5% 01811 cancèts gksbally, and which wè now, for tha first time in history, have Ihe opportunity to &liminale as a wblic health th￿at. Despite Ihe scale ol the opportunty, Ihe UK has yet lo take Ihe slep of other ￿UntrieS. such as Australia and Canada. in developing an action ￿an for cervical can￿r eliminatK)n. The UK also lags behind tre European UnK)n which, through the 8ealin9 Can¢er Plan. has gone one step further. in ￿mmItt1ng lo eliminate 811 HPV cancèrs. Thé HPV Coalition is Ih6rth)r6 èagèr to ￿ thè UK put In place a concratè plan for èliminatitsn as a matter of priority, targeted at the whole raThJe of HPV-reLated cancers and suppoth'ng acc8SS to preventativ8 interventions for all parts of the popu￿t￿)n. The Coalition will sland at the forefront of UK 5xAibym8king 8nd *ill brir¥J togelher 8 mernbership of patient organisatiOll5, professional groups, cliniuans. and 8xp8rt individuals to buikj and d8monstrat8 broad stakehokjèr consensus aTound lh6 signthrAnt - and as yèt unhamessed - opportunty tts putsue elimination in the UK. The membership wll advocate lor o)mmitment and acbon from all UK govemments to pursue eliminats'on ol the whole range ol HPV4elaled Can￿rs. in bolh men and women. On October 24th 2022, the Coalrtion was officially launched in Ihe Palac? of Westminster in an event ￿sted by long standing HPV advocate, J8ss Phillips MP, and suptx)r18d by tX)liti"￿anS from both sides of the ai51e, as well as community stakeho￿ets such as HPV Ixncer thrNers. Page 7 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES The next step for the Coali*'on will be the publicalion of a roadmap in SprirrfJ 2023 which wll prowde blueprint of how the eliminatvjn of HPV cancers can be ddivered in the UK. This will set out ambity'ous. yet r8ali5tic goals, mapping out key areas of action, induding mi18Ston8s, markers of sU￿sS, and research reeommendatsons lor a￿aS whith require further understanding. published, this wll be utilised tr) engage with policy and par1rdmentary stskehohjers to facilitate wider consensus ar(￿nd the roadmap and the uttimate goal of eliminat*Jn. An81 Cancer Foundation Anal cancèr is onè of thè 18St8st growng ￿ncerS in the Untted Stat8S, 8nd steadity increasing in thé United Kingdom. We continue to work tirelessfy lo make lrfe better lor lamil*s faong anal cancer through our programs to raise awareness. acce￿rate earfy deleth.￿. improve qualty of life, and advan￿ a cure. This year. we made Incredib￿ progress raising awareress about the need lo reforni how anal cancer thrivers are diagnosed and treated. Pe•r to Peer Support Programm• and Thrivor Education In the UK, about 1.5￿ people, and in Ihe US. aboul 9,71XJ are diagnosed wlh anal car￿er annually. An81 e8n¢er in¢iden¢e is In¢￿8$Ing and affects mortr r*c¢)b a¢ross the worfd every year. The soual stigma that 8nal cancér earriès prevents lair and equilatAé CA)nversal￿, awarènèss, and funding tts support rèsèarch and care for peop￿ with tha disease. Support and information is limrted for anal cancer Ihrivers lour word for survivors) and many thrivers never meet another anal cancer patient. The FOund8￿.0n prowde5 educational forums and 8 peer mentorirrfJ program to SLJPPOrt Ihriv8rs to ck)sè this gap. Th8 Pèèr its Péèr Supw)rt Program is 8 free servicè providèd by the Foundatson in the UK and USA lo connect pakn.ents and caregiv￿$ fac4ng challangès brought on by anal cancer with a peer who has undertaken the same joum6y. Connections are avaikble lor anyone at any carKer siage Irom d￿gnoSed to years after treatment. Volunteers listen and help thriver5 through their cancer Jwmey by sharing their own experience5 on trtr81menl, slKJm8 and social experien￿$ rdating io an anal ¢an¢er diagnosis. The pr¢gr8mme's goa15 are to improva thè livas ol thosè aff8ct*d by anal Gqncèr and givé sU￿1V0￿ a V(MC8 and a community. Tha program also matches cawivers together. At th& end of 2022. the HPVACF'S Peer to Peer Support Program included 1014 thrivers. caregvers, and peer mentors. Our online educ8b'on81 events ts)ntinue to provKltr h￿tr and rtrsourc25 lor thrivtrrs. Our 'T8kin9 Care of You.. Managing SKJe Effe¢ts From T￿alMeThI F(% An81 car￿9￿ event, leaturing expert clinicians who treat peop living wth an81 cancèr as w611 as a panèl of Ihrivéws has bè8n wewèd by over 5,000 patsp￿ by th8 and of 2022. 'Living and Thriving After Treabmenl for Amal Cancer. AddressThJ Long Tam Side Effects,, was viawed 10,700 times by the end ol the year. Anal Cane8r Patl•nt Conf8r•ne• On October 1st, 2022, the Anal Canw FOUndatic￿ hekfj Ihe second Anal Can￿r Patient Summit. Medical professunals spoke about anal cancer causes. trealments. and how to rn￿gate the various side effects of chemor8diatK)n. We 8150 heard from 8dvoc8ies vhKTr tsught us, Ihrough sharing their r)wn storie5, how to use our pe￿onal experiences to advance the fight against anal cancer. Finally, thnver5 We￿ able to network both in groups and within on&on-one sessN)ns vA)ith. for many people. was the first time they were meeting a lelh)w thriver. The c(Mrference was cre*8(I to provide an annual op5x)rlurbty for anal ￿ncer patients and caregivers to leam frotn rnedical professionaL8, connect V￿1h ex￿rtS and each Ott￿r, and take action to ernpower themselves and this cixnmunity. Page 8 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES Over 400 people registered for the Confe￿nCe from 20 countries around the worfd. Feedbad( frorn partscipants induded.. 'This was beyond outstanding" and "Great Summit Learned so much more than I thought I needed to know- Tenificr Anal Cancer Foundatson Ci>Founder Jvstine ￿rnad3 fau"lrtate(I the davs events. Experts including Drs. Joel Palefsky. Cathy Eng. and Paul Romesser spoke about anal cancer causes. treatments. emerging therapies, and quality of lrfe after trealment. Thrivers were given the opFKYtvnty to ask questions live. as well as to connect with on8 another. Anal Cancer Thriver and Activist Marcia Cross shared her own story alongside several other thnvers, guiding the audien<£ In how to use tt*ir I￿nal ex￿￿enCÈs to advance the fight 898inst 8n81 canc8r. We wouhl like to make SU￿ every famity faung anal can￿r has access to the same infomation as their doctors. RecA)rdings of the days events are now avaikqble on YouTube. We wll hold another Anal Cancer Patient Sumrnit on Oclober 21st, 2023. NCCN Tr•atm•nt Guidelines In 2021, we were thrilled to pather wilh NCCN lo cxeate the anal canw treatment guKle for p8ty'ents. enabling p81i8nls and their ¢aregNets to tske ¢harg8 of their t)wn ¢are and recovery. This yè8r. NCCN updalsd th8 guidèlinès lor 2022, 398in wilh inpul from Anal Cantw Foundation. The NatM?nal Comprehensive Cancer is an alianc8 of 31 cancer centers in the USA, reLxJgnized for dealing with cornplex andlor ra￿ Can¢￿S. NCCN Clin￿1 Guidelines are the reo)gnized standard lor clinical direction and wlicy in cancer care and are among the mosl thorough and frequently urrtyated clinical pracbce guidelines availablé in any arèa of mèdiciné. Thè intént Of the NCCN Guidelinès is to 8ssisI in the decision-making process of IndivKluals involved in cancer ca￿4nCludIng physiaans, nurses, phamiacists, payers. patients, and their families-wilh Ihe ultimate goal ol improving palient care and outcomes. This companion guide for pats'ents is the next step lorward in empoweriThJ pabents wth accEssibl8 infomiation. We hope this anal cancer tsatment guKle presents clinical infornalion in an easy-to-read format for peop with cancer and those who $UPFK)rt th&rn. Th& patienl guideline is intended to= - Equip patients and providers wth the sam& infom)abon as Ihat oftheir med￿1 team Ensure that patients, no matter where they are treated. know what the experts agree upon as the standard of Irealmenl and care - Empower patients wilh knowledge atrtxrt all of Ihw'r Ire8tsnenl arKJ ¢8ffj ¢hoic¢s - patients to 8ell-adv(K¥te ts their own best (s ANCHOR Study A ground-breaking randomis8d ￿ntrol￿d nalK)nal lrial of 4,500+ p￿>ple has Shown that anal can(xr can b8 prevented by r(>￿Ine streening and remval of precancerous cèlL%. Thè ANCHOR Study hopad to improvè patient outcomes lor peop￿ with anal precancer and cancer by finding the best way to stop anal precancer from prOg￿$Ing to Can￿r. The Anal Can￿r Foundat*)n ￿j11 and the 0￿11th)n ol organyzatsons that supported and pushed for the sludy. ANCHOR stsnds for Anal C8n¢xr HSIL OutcorT*S Researth 8WKI the study inve5twated treating anal cancer precur50r le510n5 to see rf th15 reduced the cancer risk for living with HIV. Conceived and led by An81 Can￿r Foundation Saent'fic Advisory Board Member Dr. Joel P3￿fSky, ANCHOR aimed to reuuit 5,000 people livitvJ with HIV and was randomized into ￿ groups: I￿lMent ol anal preCan￿r and a o)ntrd group. What was ANCHOR researchlng7 Page 9 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES p￿ventIon and earty detection are essenlial lo ending anal cAn￿r. Yet. desprte its gTowng incidence and mortality. there are no national screening guidelines for anal can￿r or precancer. The rates of cervical cancer reduced by 80Wts onc8 d(￿tOrS stsrbng scr8ening for and tr88ting e£rweal pr8Ggncer. The hope was that the ANCHOR study would Illustraie thal I￿3￿"n9 anal precane£r will reduce the risk of 8n81 cancer. The ANCHOR stu¢Jy had main objectives". to detemine the effectiveness of screening for and ating anal precancer. to reduce the Inciden￿ ol anal cancer in Hlv-ptssilive men and women, and lo create bank of bbod. anal swab. and tissue specimens to support critical scientsfic studies on how anal cancer progresses. There were two amis in the sludy: ami th8t received trealmenl f¢x an81 precancer and a ¢ontrol am that did Mt. Ninety percent of anal cancer is cal￿￿ by thè human pa￿lk)mavlrus IHPVI, ￿•ch can cause changes to the skin around and inside the anus. These charoes are called Th(gh￿rade squamous intraeprthelial lesions. or HSIL. Not all anal HSIL will develop into ¢anw. Most HSIL will go away on their own. but some become cancer over time and can evenlualty SFwd to other parts of the bcxjy. The incidence ol anal cancer is highest in people living with HIV. What were thg out¢ome¥7 Results were published in The New Eng￿nd Joum81 ol Medirine in June of 2022. They demonstrated th81 this reduction was as hvJh as 57%, ad)ieved through roub.ntr sctyening and renk)v81 of pocancèrous Cèlls. Addititsnal findings Includè.. A higher prevalenc8 of HSIL than an￿rApated. This was rTh)st SU￿SsIng in woman. They were expecting 10°/0 prevalence but found 47.2°k. - The study diagnosed 17 people cancer, %thich was hvJher than expected. - ThÈre w8s 8 youn9Èr median a9è at diagnosis than 8xpédÈd. There was no ￿al diffe￿nCe in age, race, or gender in those progf8ss8d to ¢an¢*r, but a 18ry9 drfference in cancer prog￿$s1On in smokers as compared lo notFsmokers. Exyrt Hour W•bln•r S*rt¢$ Whan you know what your provKlars know, you ar• •mpMr8d lo havè Th)re itFdèpth Bnd producdv& conversations toward our #1 priority.. getbng you the best care PDssibk. We bring the ex￿rtS right lo our wmrnunity 8rkY hekl our inaugurdl Extert Hour We￿.n￿r series.. ClinKal Trials 101 and Imrnunothérapy 101. featuring wiyld-rènownè(l Èxperts and 8 livè Q&A with Dr. Lee Rosen of the University of Califomia, Los Ang￿￿$, and Dr. Julius Sttsuss of thè Nats"onal Instrtutès of Hèalth holding infomiative and insighfful Sess￿$. We were ￿illed at the qualty and dopth of infcwmats'on about anal cancer they each brought directly to the communrty. Clinical Trials 101 March 18.. Cliniral Trials 101.. Dr. Rosen guided u5 Ihrough rnyths and f8cis atxjut dinical tria&, provid8d quests.ons to ask when COn￿d￿nn9 a Inal, and OUth"n￿ how to framè dintsl trials dunng tha trèatmènt journey. Imrnunothera 101 April 21. lrnmunotherapy 101.. Dr. Strauss presented on the types of irnmunotherdpies and how they work. what fadors affect resWn5e to irnmunotherapy, tK)tential 5Kle effects, and how to imrnunotherapy dinical triak. Thank you to our experts and to our parbu'pantsl Int•matlonal Anal Neoplasla Sod•ty {IANSI IANS, the Intemational Anal N￿la$la Medical Swety. ueates medical guidelines and supports research essential io preventing and Ireabng anal carKw. IANS was Crea￿ vlth a seed granl from Ihe Foundation. PagÈ10 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES IANS mission is to provide a forum for individuaLs wth a broad spectrum of background. wewFX)ints and geographic origin, an 8xch8ng8 of Kleas and diss8min81K)n of knO￿￿￿ge wardin9 the p8thDJ8n8SIS, diagnosis, treatment and preventi￿ ol anal r*oplasia. In SUPFMJrt ol this Missh￿ IANS.. Develops position papers regarding the pattwene5i5. diagr¥)sis. treatrnent and prevent￿ of anal neoplssia. - Represents the consensus opinion ol ￿Ns warding the alme toix<* to ottw profÈsskN￿I soc*tle$, publlc organizat￿ns, r8gul8tOry 8Uthonbas and govemmènlal tM*Iiès. Encourages the development ol a robust ￿searCh aga)da on the pathog•n*sis, diagnosis. treatment and prevention of anal neoplasia. Develops edUcat￿￿al rnaterials and c4Jnduct training o)urses Ihat ￿O￿Tage the enty of a broad spectrum of clinician5 into the field of anal neoplasia, and that furthers Ihe devebpm8nt and depth of 5kilts of clinici8n5 needed lo optimally dia9n059, treat and prevent 8n81 neopl851a. - Dèvelop 8ducational matarials for patients wlh anal neoplasia. On June 5th. the third day of the 2022 IANS Suentific Meebng in New York. a panel of brave and outspoken thrivers and advccales shared their experiences wilh Ihe assembled medical experts. in a session entitK8d. 'Rare and Mi5underslcx)d.. Ten Years Later Narralives and Perspe¢twe on the Anal Cancer Experience." The session was led and f8ulitaled by Patient Advc¢attr 81 IANS. M8ry-Jo Muwhy. Invited speaker Justine Almada put forward the Ftyjndation's fcrf ending tha disaase gnd called on everyone gathered to join together and RAISE their game. Fler call lor RAISE means Ihal we, ¢olkntively'. R8far to ￿MprehenSIVe ca￿, ￿?th durirvJ and after tr9abnenl Advocate for screening Invest in research for new treatments Stop the Stigma wlh connection and communty Ensure earty and acrurate diagn05iS Daun. Steven, Stephen and John gave testimony of Iheir joumeys. These We￿ raw and honest first-person stories from people who have been through Ihe isoLab"ThJ. confusing, and painful expenence of anal cancer and precancer. They gave n¢>holds*Jarred delaiL8 on vthat had happened lo them and how their lives had been changed by anal can￿r and Fffecancer. The road ahead in anal ￿nCer prevenlK)n and Irealment imtxovement 1$ kng, but the stytrntific meeting and pats.ent pan81 ma(J8 rt clèar that no one is in this 3knn8. Intormthion and Connection Th6 Foundation's anal cancer prryjram websrte features a weath of resoure8s and is a sourcè of infomiation, support. and inspiration for pats'ents and lamil*s affected by anal Can￿r. Our focus is ensuring patients gel ¢he informalh)n and support they need during (heir anal can￿r joumey. Our Living with Anal Can￿r section features infomiatiC￿ for palients at all stages of the anal can￿r joumey trorn newly diagnosed to post-trealment resources. stKh as how physical therdpy can help with anal cancer treatment re(x>v8ry. Th8 sit8 is th8 fTK)St comtKehensive 50urc8 of informatK>n on Side effects and sid8 effect mits"gatitsn dunng and after anal rancer treatment. This dwital hub is FX)pulated with personal thriver stories Ipalients. stories ol their experiences), infomiats.on atM)Ut helpful medical ￿SoUr￿$, and professional medical bodies. as well as connectK)ns lo other patients and caregivers Ihrough our Peer to Peer Supporl Program. PagÈ11 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES Our goal in 2022 continued to be ensuring that rnore anal cancer th￿ver$ have access to the information they need to face their cancer joumey through targeted outreach based on our existing supporter base and a news18tter series for p8ts'ent5 and Gqregwers, fr￿￿5￿￿ on our expert and popu18r re50urc£5. With the pandemic reduung the in-per50n resources availabk to the anal can￿r (xxnmunity, the need for communicatson was more important Ihan ever. Our communirats.ons strategy fc*)Jsed on consistency and 'uselul' inlomiats'on. with content covering treatment and research uFxJates. stories from community members. and explainers of our sefvices and ￿)W we suppcrt the anal cancer o)mmunty. ACF'S 2022 direct impact ineludes.. 130+ nèw 8n81 cAneÈr Ihrivèrs 8nd caregivèrs sKJniNJ up to bè matthed through th8 Peèr to Pèar Support Program. - 250+ anal cancer thrivers and caregivers helped by the 1..1 Palent Navigation ServicE. Peer to Peer Support signups are up 28.10 on 2020 fMJures. - 25 thrivers sharing their story publicty wth our ￿Mmunity through our Share Your Slory In￿ative. - 650+ peop￿ particip8ts.ng in our infomiats.onal forums. Overall, in 2022. ACF ijiredy served over 1.100 anal cancer patients through our best4n-class patient programs. at no cost to them. interest in our reSOur￿S in¢￿8$ed with web session duration up 17% over 2021, and counuess peopk? wll benefil from OUT adv￿a￿￿. this year and for several years to cune. Gtyng forward. wtr will ¢ontinvtr wtykiThJ to prov￿* all the support Ihe anal cjjnmunity needs. LIJOKING AHEAD.. 2023 As we look ahead. the HPV and Anal Cancer Foundabcffj (￿tinUeS to seek the most effective rnethods to prevent HPV and cure the cancers il causes. Tha Foundatk)n wll continuè lo work brelessty lo èliminate all HPV-relat8d eAnc8rs by furth8rfng pub15c policy and saentifie debate, eliciting further profeS￿onal and expert support, encouraging the devekjpment ol regional inrtiatives on vaccinatiro boys, and demonstralry why li is imp￿￿nt to protect all children against HPV at the recommended age. Th8 UK t*g8n V8e£in8￿n9 Iws ￿aInSt HPV in Sèptèmbèr 2019 and ￿ will o￿tinU& to work with stakehokjèrs in the HPV-reL4ted distsase space 10 ensure that uptake for this cancer-preventing intervention among 12-13-year-old boys is as hKJh as possible. The work of the HPV Coalrtion wll be important in ensuring the unpre￿ented ¢)pportunity lo eliminate HPV Can￿rS in the United Kingdom is not missed on the back ol the interrupts'on caused by the pandemi Our advocacy efforts in Eur¢po ￿th the EurO￿an Cancer Organisation and HPV Action Nelwork to attain gend8r neutral HPV vaccination acmss th* conts"nènt, conb"nu8 apacè. With th8 EU 88atsng Cane8r Plan speaficaI￿ induding actions on HPV cancers ￿thin its ￿Mit. we have a mandate to gain support and empower slaketrdders within member slales lo eliminale HPV cancers. With over 40% of Can￿rS in the region preventable. Ihe extension of HPV v8wnat1c￿ projrammes to protect boys as well as girL8 provides a recognised and effeotNe means to tsthle Gancer. By continuing io buikl our evidence base, seek and ideritify barrier5 to uptak8 in EC m8Tnb8r (xjuntries, and launch advtracy groups in rTTr8mber stat8s, we are Ix)nfKlent that mor8 cwntriès ¥wll sign up tr) gendar nèutral Fxoteclm inthlwas. Through the NOMAN is an Island Campatgn. ￿Let￿)ratIonS advocates and *islators. media attention and alhletic event particgpation. a broader audience is underslanding the imFM)rtance of protecting all children againsl HPV. Our flagship 8ar(%lon8 - Ib￿8.. Row to End HPV event wll hokl its 10-year anniversary, serving as an opp(Ktunrty to ga￿a￿lse both k)ng-StarKling and new Sup￿rterS and fijrthering the reach ol our message to prevent 5% 01 cancer. With the NOMAN side of the organisation leading on HPV-related activities. we will continue to pather wilh the Haute Route on lurther cydiro events as Iheir European Charity Partner, and continue to edvcale atM)u¢ our ability to end HPV canctrs. PagÈ12 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 OBJECTIVES ANO ACTIVITIES We will continue to push for legislative. research and poli￿ changes to end anal can￿r and improve the live5 of those affected by it. We are excrted by the response to our Patsent Surnmrt and 'Ask the Experf sessions 8nd look forward to providing more touthw)ints fix i)ur (x)mmunity wth these and th8 pat18nt cx)nfer8nc8 in 2023. Our Peer to Peer supwrt program retains rts imwrtan(* in supporting and emw)wÈring anal cancèr survivors and raregivers. Uti1￿1rng digital and live pklfomis, we will reach a wider prowrtion of the anal cancer community. enabling patients lo gain answers lo the cotKems they have and to connect lo other anal cancer patient experiences. We thank all ol our donors and l(K)k l(xward to continuing thè missK)n to em￿Wer anal cancer pats'ents and 8ec8lerat8 preV￿￿"0n and r8s8arch methods Ihat Èliminaiè an* can(*r and th8 wrus that ¢>usès th8 majorty ol cases. HPV. Publlc ben8flt Th8 trust8*s hav8 rÈf8fTed to the guidancè t￿￿1n8￿ in Ihè Chanty CommissK)n's general guidancè on public benefit when reviewing th¢ charity's aims arrfl objecb'ves aThJ in planning future actwits"gs. FINANCIAL REVIEW Reserves pollcy The reserves policy is to maintain a minimum that enables Ihe (wganlsatic￿ to meet its financial commitments for the year, including grants. ￿ntractS. and stsff saLaries. Golng concem As stated in note 19. the Trustees have consmlered lh8 effect of the c*Jrrent ecLJnomic climate. The Trustees consider that the current economic climaie is likety Io cause disrup1*￿ lo the Chantys acbvities but are confident Ihal current reserve5 and future income will be svffvent to ensure that the Charity r8main5 a going ¢oneern for a peritKI of at lea$1 r￿￿1h$ from the date of apk¥oval of Ihsss finantyal Ststements a$ ￿11 as lor the foreseeable future. STRUCTURE, GOVERNANCE AND MANAGEMENT Gov6mlng docum6nt, structur• and management The charity is controlled by its goveming document. a deed of trusl, and conststutes a limited company, limited by guarantee. as defined by ihe Companies Act 2006. The HPV and An81 Cancor Found8lK)n Limited 1$ a United Kin￿10￿ IUKI subw'diary of The HPV 8nd Anal Canc6r Foundation in thè Unitad Stalès of Amèrica IUSAI (Charity EIN. 27-32175201. which was ast8blish•d April 2010. All WO￿ undertaken by the UK FouThJation is in Cc41atM)raI￿ with its pa￿nt. The HPV and Anal Cancer Foundat￿ Limiled is a d￿rita￿e company limrted by shares. ino)rporated in the UK on the 20 February 2012 and registe￿ as a charity on the 25 May 2012. The company wa5 established through it5 Article5 01 Association, whith established the objects and tK)wers of the tharitab￿ company. Al shares in the crnipany am ow)6d by Thè HPV and AJ)al Can￿r Foundatth in the USA. The HPV and Anal Cancer Foundal*)n t4)aTd wnsisls of lour members. The Trustees a￿ responsible for the legal, finanrial, program and rnanagerrenl oversight of the charity. The board held its annual meebng on D8c8mb8r 18. The daity responSi￿.11t￿S ar￿ missK)n of the FourKlation are executed by the tearns in the USA and the UK. In the latter, the Diredw of UK Opw*K)ns is responwble the (x)(xdinalK)n of day-i(Trday acbvit18S. When the Trustees advertise lor new t*)ard members. candhlales are sourced from the general public as well as contacts of the charity. A diverse mix of skilL8 and backgrounds a￿ sought. Prospective Irustees are interviewed prior to appoInt￿￿￿t. As part of their induclK)n, new twstees are given a fvll introd(J¢tion to the work of Th8 HPV and Anal Cancer Foundation in add￿.0￿ to copies of the organization'5 financial docum8nis, bylaws and FKJlicEs. PagÈ13 THE HPV AND ANAL CANCER FOUNDATION UMITED R8POrt of the Trustees for the Year Ended 31 December 2022 STRUCTURE, GOVERNANCE AND MANAGEMENT Risk management Th8 trust885 hav8 8 duty to id8ntify 8nd r8vi8W th8 risks to whKth th8 (tharity is 8xw)S8d 8nd to ensur8 appropriate controls are in pla￿ to provKle re&8onabk assufance against fraud and error.The trustees of the Foundation hdd the responsibility of safeguarding the d)aritys assets and systems a￿ in pla￿ to mitigate those risks whth the charity may fa￿. This r8POrt has been pr8p8r8d in 8fAX)rd8nr* wilh th8 swial prO￿S1On$ of Part 15 of th8 Compani8s Act 2006 relabng to small companies. 27.09.2023 Approved by order of the board oftrustees on ............................................. and swJned on its behaK by.. T Alrnada- Trustee Page 14 IndÈpÈndent Examinerf$ Report to the Tntste¢s of The HPV and Anal Cancer Foundatlon Limited Independent examinerf5 report to the trustees of The HPV and Anal Cancer Foundation Limited Ilhe Company'l I ￿port to the charity tnjstees ￿ my examinat*Jn of the amnis of the Company for the year ended 31 December 2022. R•sponslbllltl8s and basls of r•port As the charity's trustees of the Company laThJ aLso its direclors for Ihe purposes of company lawl you are responsible for the preparation of the accounts in accordance wilh the requirements of ihe Companies Act 2006 Ilhe 2006 Acri. Having satisfied mysew that the a￿oUnt$ of the Company are not required to be audiled urvjer Part 16 of the 2006 Act and are eligible for independent examination. I report in respect of my examination ol your charity's accounts as carried out under Section 145 01 the Charities Act 2011 Ilhe 2011 ACYI. In carrying out my examination I have folk)wed the Directions given by the Charity Commisgon under Section 145151 Ibl of the 2011 Act. Independent examinerfs statement I have completed my examInath￿. I conffimi thal matters have come lo my attention in o)nnection wth the examination giving me cause to believe.. accounting r8cords werè not kèpl in resp8cI of the Cempany as r8quir8d by Sèetion 386 01 thè 2006 Act,, or the accounts do not accord those reccrfds: the accounts do not comply with the accounting requ1￿ments of Section 396 of the 2006 Act other ¢h8n any requirement that the actounls give a Inje and fair view which is not a matter considered as part of an independent examinatK)n,' or tha aceounls havè not b8en prèparéd in 8ccor(lan(* with Ihè methods And prin{)￿8$ ol thè Sl8t8mènt of Recommended practi￿ lor accoUn￿ng and repthng by charitses lapplica￿e lo charities prepanng their accounts in accordance wth the FinancAal ReportiThJ Stst)dard applKabl8 in lh8 UK and Republic of Ireland IFRS 10211. I have no con¢ems and have c4)mtr *T0s8 no other mattern ￿ o)nnedion wilh the examination to which atteniion shoukl bg drawn in Ihis r¢kw)t in lo enaN¥ a wpgr und¥rstarKling of th& a¢counts to b& reached. Richard Billinghurst Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD 2810912023 Date.. PagÈ15 THE HPV AND ANAL CANCER FOUNDATION UMITED statement of Financial Activities Ilncorporating an Income and Expendlture Account) for the Year Ended 31 D8C8mber 2022 2022 Totsl funds 2021 Total funds Un￿Stricted fvnds Reslricted funds INCOME AND ENDOWMENTS FROM Donations and legacies 2,083 other tr8ding acts'vitvas Investment income 64.776 22 64.TT6 22 202,664 Total 154.892 154.892 204,749 EXPENDITURE ON Raising funds 16,407 16,407 56,981 CharStablo actSvltl•8 Care and Supwrt Awareness Raising & Educatl Research for a Cure 47.957 103,849 4.796 47.957 103.849 4.796 47.743 146,825 4.325 Total 173,009 173,009 255,874 NET INCOMEIIEXPENOITUREI 118,1171 118,1171 151,1251 RECONCILIATION OF FUNDS Total lunds brought forward 62.964 13,100 76.lJ64 127,189 TOTAL FUNDS CARRIED FORWARO 44.847 13,100 57,947 76,064 The notes fomi part of Ihese finarKial sl*wnents Page16 THE HPV AND ANAL CANCER FOUNDATION UMITED IREGISTERED NUMBER: 0795S4S11 Balane8 Sheet 31 December 2022 2022 2021 Notes CURRENT ASSETS Debtors Cash at bank 14 831 67,779 327 83,806 68.610 84.133 CREDITORS AmoLJnts falling duè wilhin onè yèar 15 110,6631 18,0691 NET CURRENT ASSETS 57.947 76.064 TOTAL ASSETS LESS CURRENT UABILITIES 57,947 76,064 NET ASSETS 57,947 76.064 FUNDS Unrestricted ftjnds Restricted funds 17 44.847 13,100 62,964 13,100 TOTAL FUNDS 57,947 76,064 The ¢haritsb￿ ¢omp8ny is enbued to exempti￿ audit undw Sadth 477 of the Companies Act 2006 for thg year ond¢d 31 D￿mber 2022. The members have not required the company lo obtain an audil of its financAal ststements for the year ended 31 Decernber 2022 in acwrdance W￿th Section 476 ofthe Compan￿$ Act The trustees acknO￿ad9￿ thèir r6$pon$ibilities lor lal ensuring that the charitable company keeps accounb.ng reC(￿￿S that compty wth Sectvjns 386 and 387 of the Companies Act 2006 and Ibl weparing financial slalemenls ¥thich gNe a true and lair view of the stale of affairs of the charitable company as al the end of eath finanaal year and ol its surplus or def ut for each financial year in accordance with the reqvirernents of Seclk)ns 394 and 395 and which otherbvise compty with ￿e requirements of the Companies Act 2(X)6 reL4b"ng to finantxal statemen￿, 50 far as applicab18 to the charrtabla company. These financial statements have been prepared in wth Ihe provisions ap￿icab￿ io charitable companies subjec¢ to the small crynpanies regiTh*. Th8 financi81 statements were approved by lh8 808rd (rf TnJste8s and authorised for issue on 27.092023 .. and We￿ soned on its behaw by". Type text here T Almada- Trustee The notes form part of Ihese finarKial sl*ements Page17 THE HPV AND ANAL CANCER FOUNDATION UMITED Notes to the Financial Statements for the Year Ended 31 December 2022 ACCOUNTING POLICIES Basls of pr•parlng th• finanelal stat•m•nts The financial statements of Ihe charitable company, whid) is a public benefit entity under FRS 102, have been p￿pared in accudance with the Charits"es SORP IFRS 1021 'Accounts'ng and Repoiting by Charities.. Statement of Recommended Practice ap￿ICable to charities preparing their ac£ounts in accordance with ¢he Financial ReFK)rbng Standard applicabb in the UK and Republic of Ireland IFRS 1021 leffectwe 1 January 20191., Financial RepO￿ng Standard 102 The Financial R8POrting Standard applicable in the UK and Republic ol Ireland. and the Companies Act 2006. Thè financial statements have been prepared U￿er the historical cost convention. Golng Conc•rn The Irustw consKl$r Ihat there are no material un¢wtsintie$ atrM)Ut the Charlvs abilty to ¢ontintJ& as a going concem. Flnanelal rèportlno standard 102- rtdue•d dl*elo8ur• èxèmptlo The charitable company has taken advantsge of Ihe lolk)wing disdosure exemptions in preparing these linanoal slalemènls, as p•milt•d by FRS 302 Thè Financaal Rep￿.n9 Standard applicablè in the UK and Republic of Ireland.: Ihe requirements of SeclKJn 7 Ststement of Cash Fl)ws. Income l income is recognised in the Statemenl of Financial Activits'es once the charity has entitlement to tre funds. il 15 probable Ihal the income wll be ¥ec8sved and the amounl can be measured reliably. Expendlture Liabilities are recognised as expenditwe as scon as there is a 18gal or constructive obligatKJn comrnilbng the charity to that expendilure. rt is probab18 that a transfer ol econornic benefits wll be required in settlement and the amwnt ol Ihe obliga1￿)n can be rnea5ured reliably. Expenditu￿ is accounted lor ¢)n an a(xru815 ba￿5 8fKI h85 been da55ified under headings that aggregate all w$1 r6Lglèd tts tha cal6gory. Wharè costs canMt bè diractly attribulèd lo particular hèadings thèy h8v8 baèn allocated to activrties on a basis consslenl ￿th the use of resojrces. Grants offered subject to ￿lch have not been fflel al the year end date are Mted as commilmenl but nol accrued as ex￿r￿lItUTe. Tanglble fix•d assets Depwialion is provided al Ihe annual rates in order to wriie off each asset over its estimated uselul lile. Ocean romng boat and accessories. ov6r3 ￿rS Taxation The charity is exempt from cCYFw)rabC￿ lax on its Ch￿rta￿e athibes. Fund a¢¢ounting Unrestricted fLJnds c8n be uwl in a(XXjrdan￿ Ihg tharilable obiecbv88 at the disrxetion of Ihe trustees. Restricted funds can onty be used for particular restricted pu￿ within the objects ol the charity. Restrictions arise when speufied by Ihe donor or vthen funds a￿ raised for partycular restricted Page 18 (x)ntinLJed... THE HPV AND ANAL CANCER FOUNDATION UMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2022 ACCOUNTING POLICIES- ￿nIlTrUed Fund aeeountlng Further explanation of the nabjre and pUr￿￿e ol eath tund is induded in the notes to the finanelal statements. P•nslon costs and othèr post4•tlf•m•nt b￿•ffts The charitable company operates a defined coniribution pensKsn scheme. Contributions payable to the charitable company's pension S(kn￿e charged to Ihe Statemenl ol Financial Activib'es in the period to which they relate. Jl￿gM•nts and k•y of •stlmatlon une•rtalnty No judgement (apart from those InvofvirKJ eslimatesl have been made in the process ol applyng the above accounting FM)licies that have a sMJnificant effect on amounts fecognised in the financial staternents. OTHER TRADING ACTh4TIES 2022 2021 Fundraising events 64,776 202,664 INVESTMENT INCOME 2022 2021 Deposit accounl interest 22 RAISING FUNDS Rolilng donatlon$ and llgacl 2022 2021 Staff costs Dev8knpm8nt &m￿n$•$ O￿Or software subscription Evenl ExKEnses SupFK)rt costs IOp6ratingl 6.$8S 5,9CKJ 118 2.002 46,842 2,119 2.167 4,626 2,987 16.407 56,981 Page 19 (x)ntinLJed... THE HPV AND ANAL CANCER FOUNDATION UMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2022 CHAR ￿ABLE ACTNMES COSTS Grant funding of Direct 8ctiwti8S Costs158è (see note note 6) Support (X)5ts lsee note 81 Totals Care and Support Awareness Raisiro & EducatMJn R8search fer a Cure 31.802 65.467 3.092 16,155 21,313 1.704 47,957 103,849 4,796 17,069 100.361 17.1)69 39.172 156,602 DIRECT COSTS OF CHARITABLE ACTMTIES 2Q22 2021 Staff costs Deveknpmenl Exwns¢s Mad(eting Miscellaneous Expense Event ExFenses Media Intomet aryl W&bslt& 37,310 3.032 34,297 2.104 4,626 17,552 33,429 5.035 43,064 1,682 46,843 20,778 100,381 150,831 GRANTS PAYABLE 2022 2021 Awareness RaisiTrJ & EducatK 17,069 17,365 Tha total grants paK1 to inslitulths during thè yèarwas 8s folkms.. 2Q22 2021 European Cancer Organi5ation 17,069 17,365 Page 20 (x)ntinLJed... THE HPV AND ANAL CANCER FOUNDATION UMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2022 SUPPORT COSTS Goveman cx)sts Finance Totals Raising donabons and legacaes C8r8 and Support Awareness Raising & Educath Research lor 8 Cure 2.016 14.472 17.949 1.252 909 1.576 3,151 424 2,987 16.155 21,313 1,704 107 213 410 35.689 6,060 42,159 Supwrt eosts, incI￿Je